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Abstract 
 
Background 
Pulmonary metastasectomy (PM) is routinely performed in colorectal cancer (CRC) patients with 
oligometastatic spreading to the lungs. Patients with an aggressive tumor phenotype should be 
excluded from PM, since its benefit is outweighed by early tumor recurrence and impaired prognosis. 
Expression of PD-1 and its ligands are prognostic factors in a variety of primary tumors. However, 
their impact on patients’ outcome in the setting of PM for CRC has not been evaluated before. 
Material and Methods 
53 CRC patients with pulmonary metastases receiving PM with curative intent between April 2009 
and November 2013 were included in this study. Tissue samples of resected pulmonary metastases 
and available corresponding primary tumors were collected and assessed by immunohistochemistry 
for PD-1, PD-L1 and PD-L2 expression by tumor-infiltrating lymphocytes (TILs) and tumor cells. 
Results were correlated with clinical outcome parameters. 
Results 
PD-1 and PD-L1 expression was commonly found in TILs and tumor cells. Expression levels were 
significantly different between metastases and primary tumors. High PD-1 expression by TILs was 
associated with impaired overall survival (low vs high expression (mean, 95% CI): 78 months (60-96) 
vs 35 months (25-44); p=0.011). Additionally, the subgroup of patients, who experienced an 
upgrading in their TILs/PD1 status between primary and metastasis had a worse survival outcome 
compared to patients with the same grade or a downgrading (34 months (26-42) vs 108 months (87-
129); p<0.001). 
Conclusions 
PD-1 expression by TILs is a strong prognostic marker in CRC patients with pulmonary spreading 
treated by PM. Moreover, this study provides a rationale for a therapeutic PD-1 pathway blockade in 
the treatment of CRC lung metastases. Further studies are warranted to confirm these findings in a 
larger study cohort 
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Introduction 
Pulmonary metastasectomy (PM) is one of the corner stones in the treatment of oligometastasized 
colorectal cancer (CRC). By removing all gross tumor spreading to the lungs, 5-year survival rates of 
up to 50-70% can be achieved.1, 2 This is in strong contrast to survival rates of patients, who do not 
qualify for a surgical treatment, with only 1 out of 10 patients being alive at 5 years.3 One of the main 
problems in PM is the selection of patients for the procedure. Most thoracic surgeons are reluctant 
to offer PM to patients with an aggressive tumor phenotype. In these cases, a removal of pulmonary 
metastases is frequently challenged by an early tumor recurrence, thus exposing patients mainly to 
the risks of an operation without a clear oncological benefit. To date there is a lack of clear selection 
criteria for PM in patients with CRC. Recently, markers that determine tumor behavior and 
aggressiveness have been in the spotlight of research.4, 5 
Programmed death-1 (PD-1) and its ligands PD-L1 and PD-L2 are important immune checkpoints. PD-
1 is an inhibitory co-signal on activated lymphocytes and plays a crucial role in regulating the 
magnitude and quality of T-cell responses. Immunogenic tumors can escape immune surveillance by 
an upregulation of PD-1 ligands and thus leading to an inactivation of the endogenous anti-tumor 
immune defense. Blocking of the PD-1 pathway by therapeutic antibodies is a novel targeted 
therapy, which counteracts PD-1 dependent tumor immune escape mechanisms. In clinical trials, PD-
1 inhibitors have been proven effective in patients with advanced melanoma, renal cell carcinoma, 
non-small-cell lung cancer, and colorectal carcinoma.6 
A prognostic impact of PD-1 and PD-L1 expression has been described for several tumor entities e.g. 
breast cancer, hepatocellular carcinoma and esophageal cancer.7 8 9 However, in primary CRC PD-1 
and PD-L1 expression are is paradoxically associated with favorable outcome parameters. PD-1 and 
PD-L1 expressing tumor-infiltrating lymphocytes (TIL) at the primary tumor site lead to prolonged 
recurrence free and overall survival.10, 11 This unique finding in CRC has been controversially 
discussed in the literature and is explained by the gut specific microenvironment and particular 
features of the intestinal immune system. 
To the best of our knowledge the expression of PD-1 and its ligands has not been described in CRC 
lung metastases. Furthermore, its prognostic impact on outcome parameters in patients receiving 
curative PM has not been evaluated before.  
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Material and Methods 
Study population 
53 CRC patients with pulmonary metastases receiving PM with curative intent between April 2009 
and November 2013 were included in this single-center study. In the case a PM has been performed 
before the inclusion period, the specimen of the first PM was also assessed. For 31 (58%) patients 
paraffin embedded specimens from the primary tumor were available. Tumor staging prior to 
metastasectomy was performed by abdominal and thoracic computed tomography (CT) scan. In case 
of an inconclusive CT, positron emission tomography (PET) was added to exclude extrathoracic 
spreading. All patients were operated through a muscle-sparing anterolateral or posterior incision. 
Lungs were bimanually palpated for occult lesions and a lymph nodes sampling was performed. 
Complete resection (R0) was achieved in all patients. Patients were postoperatively followed-up in 
three-months intervals with chest and abdominal CT scans during the first year and were seen every 
six months thereafter. 
Lung metastasis free survival (LMFS) was defined as the time between the diagnosis of the primary 
tumor and the diagnosis of metastatic spread to the lungs. Time to recurrence represented the time 
between PM and the first evidence of metastatic recurrence at any site. Overall survival (OS) was 
defined as the period of time between pulmonary metastasectomy and death of any cause. 
This study was approved by the ethics committee of the Medical University of Vienna (EK#: 
1097/2014) and was performed according to the Declaration of Helsinki and the Good Scientific 
Practice guidelines of the Medical University of Vienna. 
 
Immunohistochemistry 
3-5µm thick sections were deparaffinized and rehydrated in graded series: X-TRA-Solv 8 (Medite, # 
41-5212-00) - 15 min at 68°C; Xylol – 5 min room temperature (RT), 100% EtOH - 5 min RT; 96% EtOH 
- 5 min RT; 80% EtOH - 5 min RT; distilled water - 2 min RT. Antigen retrieval with target retrieval 
solution (pH9) was performed. For this purpose the slides were heated to 115ºC for 10 min in Dako 
Cytomation Pascal Pressure Cooker. After cooling to RT and washing with TBS buffer, 3% hydrogen 
peroxide in distilled water was used to block the endogenous peroxidase activity (10 min, RT). The 
following antibodies were used for PD stains: anti-human PD1 antibody (R&D Systems, # AF 1086, 
dilution 1:20), PD-L1 (Cell Signaling, clone: E1L3N, dilution: 1:25), PD-L2 (Cell Signaling, clone: D7U8C, 
dilution: 1:25). The slides were automatically processed with a Dako Autostainer Plus System. 
Visualization was implemented with streptavidin conjugated to alkaline phosphatase. Cell nuclei 
were counterstained by Mayer’s hematoxylin. 
For each slide, four different areas of tumor tissue were selected for analysis. Tumor cells and tumor-
infiltrating lymphocytes in these areas were independently evaluated by two investigators blinded to 
the clinical data. If the rating differed, the slide was re-discussed and a consensus was found using a 
multi-head microscope. Slides were examined at ×400 magnification, and the staining rate 
(percentage of tumor cells and lymphocytes showing positive staining) was determined. PD-1, PD-L1 
and PD-L2 expression was categorized into 0: no positive cells, 1+: 5-25% of cells, 2+: 26-50% of cells, 
3+: 51-75% of cells and 4+: 76-100% of cells. For some analysis a dichotomization was used. 0-50% 
positive PD-1 cells were defined as PD-1low, 51-100% positive PD-1 cells as PD-1high. 
Immunostaining for CD3 (clone SP7, #RM9107-S1, Thermo Fisher Scientific, Cheshire, UK), CD8 (clone 
C8/144B, #M7103, Dako, Glostrup, Denmark), CD45RO (clone UCHL1, #M074201, Dako, Glostrup, 
Denmark) were performed using an autostainer (Benchmark Ultra, Ventana Medical Systems, 
Tuscon, USA), as previously described.12 In negative controls the primary antibody was omitted. A 
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mediastinal lymph node served as positive control. As previously published, tumor-infiltrating 
lymphocytes were classified semi-quantitatively by two independent observers.12 The following score 
for TIL was used: scattered (+), intermediate (2+), dense infiltrate (3+), very dense infiltrate (4+). 
Grades of none (-), sparse (1+), intermediate (2+), high (3+) were used to classify the proportion of 
CD8+ or CD45RO+ cells in the immune infiltrate. 
 
Statistical analysis  
All data were evaluated using SPSS 23 (SPSS Inc., Chicago, USA). Nominal variables were compared 
using Fisher’s exact test and chi-square test. Correlations were calculated using the Kendall-Tau 
equation. Survival curves were estimated by Kaplan-Meier plots and the differences between the 
groups were compared using the log-rank test. All performed tests were two-sided. P-values < 0.05 
were considered statistically significant. Due to the hypothesis generating approach of the study no 
correction for multiple testing was applied.13 
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Results 
Patients’ characteristics  
A total of 53 (30 male and 23 female) patients were included in the study. The primary tumor site 
was colon for 57% and rectum for 43% of patients. Most patients were in UICC stage III and IV at the 
time of prognosis with a high number of already N positive tumors. Sixteen patients had a previous 
liver metastasectomy before they were operated for their pulmonary nodules. The majority of 
patients (76%) presented with a singular lung metastasis. Uniformingly, a high number had received 
chemotherapeutic treatment(s) before metastasectomy. 40 out of 53 patients were treated with 
pseudo-adjuvant chemotherapy after resection of pulmonary metastases. None of the patients 
received a PD-1 blocking agent during the study period. The median follow-up after metastasectomy 
was 35 months (range 4-137). Patients’ characteristics are summarized in Table 1. 
 
Characterization of the immune-infiltrate 
A lymphocytic immune infiltrate was seen in nearly all metastases with a broad distribution ranging 
from scattered to very dense infiltrates. In most patients the immune infiltrate consisted of a high 
proportion of CD8+ and CD45RO+ lymphocytes. A detailed description of tumor-infiltrating 
lymphocytes is presented in Table 2. 
 
Density and distribution of PD-1, PD-L1 and PD-L2 in pulmonary metastases 
Quality of Immunohistochemical stainings was sufficient in 52/53 (98.1%) for PD-1, 51/53 (96.2%) for 
PD-L1 and 52/53 (98.1%) for PD-L2 stainings, respectively. A detailed list of the density of PD-1 and 
its ligands in TILs and tumor cells is shown in Table 2 and representative images are provided in 
Figure 1. A high number of TILs were positive for PD-1. Although staining intensity was generally 
lower in tumor cells, PD-1 expression was also a commonly found feature on malignant cells. PD-L1 
was frequently expressed by TILs as well as tumor cells. However, PD-L2 expressing tumor cells were 
only found in three patients and TILs were all negative for PD-L2. There was no association of PD-1 
and PD-L1 expression on tumor cells and TILs with clinicopathological characteristics of the patients 
(Table 3). 
 
Correlation of PD-1 and PD-L1 expression in pulmonary metastases and corresponding primary CRC 
The pattern of PD-1 and PD-L1 expression was distinct between pulmonary metastases and their 
corresponding primaries (Figure 2). There was an upgrading in TILs/PD-1 expression in 14 patients 
(52%), seven patients (26%) had a similar expression and six patients (22%) had a lower PD-1 
expression in their metastasis compared to the primary tumor. Contrarily, the expression of PD-L1 in 
TILs was less variable between primary tumor and metastasis. Fifteen patients (57%) were classified 
the same grade, but only four and seven patients were upgraded and downgraded, respectively. 
Changes between PD-L1 expression of TILs and tumor cells between primary tumors and metastases 
are summarized in Suppl. Table 1. 
 
Impact of PD-1 and PD-L1 expression on outcome parameters 
Univariate outcome analyses of recurrence-free survival and overall survival after pulmonary 
metastasectomy were calculated by log-rank tests. Neither the expression of PD-1 nor its ligands by 
TILs were prognostic for time to recurrence (Figure 3A, Figure 4A). However, PD-1 expression on TILs 
was associated with impaired overall survival (low vs high (mean, 95% CI): 78 months (60-96) vs 35 
months (25-44); p=0.011; Figure 3B, Table 4). Additionally, the subgroup of patients, who 
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experienced an upgrading in their TILs/PD1 status had a worse survival outcome compared to 
patients with the same grade or a downgrading (34 months (26-42) vs 108 months (87-129); p<0.001, 
Figure 3C). The prognostic impact of PD-L1 expression on TILs was less obvious. There was a trend 
towards impaired survival in patients with TILs/PD-L1 upregulation compared to patients with the 
same or less PD-L1 positive TILs (29 months (22-36) vs 84 months (63-106); p=0.119, Figure 4C, Table 
4). Expression of PD-1 and PD-L1 on tumor cells was not associated with outcome parameters (Table 
4). 
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Discussion 
The aim of this study was to evaluate the expression of PD-1 and its ligands PD-L1 and PD-L2 in 
pulmonary metastases from CRC and to correlate the expression pattern with clinical outcome 
parameters. We found that PD-1 and PD-L1 was highly abundant in TILs in pulmonary nodules as well 
as in corresponding primary tumors, whereas PD-L2 was only found sporadically. Interestingly, there 
was a significant heterogeneity of PD-1 and PD-L1 expression between pulmonary metastases and 
corresponding primaries. High PD-1 expression of TILs in pulmonary metastases was a predictor of 
impaired survival, with the worst prognosis in patients who had an upgrading in their TILs/PD-1 
status between primary and metastasis. PD-L1 expression did not impact overall survival, however, 
patients with an upgrading of their TILs/PD-L1 showed a trend towards worse outcome. 
To the best of our knowledge this is the first structured evaluation of PD-1 expression and its ligands 
in pulmonary metastases from CRC. The PD1/PD-L1 axis is considered an essential immune 
checkpoint. PD-1 is primarily expressed by activated lymphocytes and upon triggering by its ligands 
(PD-L1 and PD-L2) it can represses Th1 cytotoxic immune responses.14  
Tumor-infiltrating lymphocytes are an important endogenous defense mechanism against cancer. 
High levels of TILs are associated with a favorable prognosis in various malignancies including lung, 
kidney, breast and colorectal cancer.15-18 Especially in CRC CD3+, CD8+ and CD45RO+ TILs have been 
extensively studied and recently an international consortium was founded to implement a novel 
staging system including the immune infiltrate (“Immunoscore”).19 High expression of PD-L1 in the 
tumor microenvironment can lead to an escape from this tumor-specific T-cell immunity. 
Consequently, therapeutic PD-1 blocking antibodies have been developed to counteract this 
phenomenon. In clinical trials, PD-1 inhibitors were successfully tested in patients with advanced 
melanoma, renal cell carcinoma, non-small-cell lung cancer, as well as subsets of colorectal 
carcinoma.6 This concept of TILs re-sensibilization by PD-1 pathway blockers has recently been 
challenged by the observation that anti-PD-1 cancer therapies are also effective in low immunogenic 
tumors. An explantation for this is the fact, that PD-1 is also expressed by cancer cells, although to a 
lesser extent. Engaging this cancer intrinsic PD-1 results in increased tumor growth and is 
downstream mediated by the mTOR pathway.20 21 Based on these findings, we also evaluated PD-1 
and PD-L1 on cancer cells. Both proteins were present in a high percentage of CRC tumor cells. 
Despite this fact, expression levels did not correlate with clinical outcome parameters (Table 4). 
Nevertheless, the high number of PD-1 and PD-L1 positive tumor cells in CRC lung metastasis 
provides a further rationale for a future application of therapeutic PD-1 blockage in the setting of 
pulmonary spreading.  
PD-L1 can be expressed by a variety of cell types, including lymphocytes, endothelial and epithelial 
cells. Contrarily, PD-L2 expression is limited to antigen presenting cells and macrophages.22 PD-L2 has 
also been shown to be expressed by some solid cancers as endometrium cancer and hepatocellular 
cancer.23, 24 In our patients we did not find PD-L2 positive cells in the lymphocytic infiltrate and only 
insignificant expression on tumor cells. We therefore, excuded PD-L2 from further analysis, since its 
impact on tumor biology and immunosurveillance can be considered minimal. 
Linking the number of TILs with their PD-1/PD-L1 expression status is an aspect, which has not been 
addressed sufficiently in previous studies. The impact of PD-1/PD-L1 axis on immunogenic tumors 
should theoretically correlate with the density of the immune infiltrate. Despite the fact, that our 
study population was small, patients with a high number of CD8+ TILs but low expression of PD-1 had 
the best prognosis with a mean survival of 64 months (48-79). Patients with only few CD8+ cells and 
expressing PD-1 had the worst prognosis of only 28 months (22-34). Patients with low CD8+ numbers 
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but low expression of PD-1 accordingly showed intermediated outcome of a mean survival time of 41 
months (24-59). 
It is commonly accepted within the thoracic surgical and oncological community that patients, who 
have a high likelihood of early recurrence, should not undergo PM. Despite this general agreement, 
there is a lack of knowledge on prognostic factors for this group of patients. The indication for PM is 
still based on clinical features, which have been proposed in the 1970s.4 The disease free interval 
between primary and pulmonary metastasis, the number of pulmonary nodules and available 
alternative treatment regimens are mostly used selection criteria. Recently, several attempts have 
been made to link markers of tumor biology with patients’ outcome. We have previously shown that 
the immune cellular infiltrate as well as markers of inflammation are strongly associated with 
recurrence free and overall survival of PM for CRC.12, 25 This study extends these findings by showing 
that the PD-1 pathway is a valid prognostic factor in those patients. Additionally, it provides a 
rationale for the therapeutic feasibility of PD-1 blockage in this subset of CRC patients. 
The prognostic role of PD-1 and PD-L1 expression in primary CRC is still a matter of discussion.10, 26 
Unlike most tumors, in which PD-1 overexpression clearly correlates with impaired survival, PD-1 
expressions seems to be paradoxically associated with improved outcome in primary CRC.10, 11 This is 
possibly based on specific features of the intestine immune system, which is constantly exposed to 
commensal microbiota. Furthermore, expression of PD-L1 in primary rectal cancer has been shown 
to be rare or even absent.27 A similar paradox is the fact that in primary CRC regulatory T-cells (Tregs) 
are associated with improved survival, whereas they are a poor prognostic factor in most other solid 
tumors.28 The local immune response in the lung seems to be profoundly different from the intestine 
immune system and PD-1/PD-L1 expression of lung cancer infiltrating TILs is associated with poor 
clinical outcome.29 This spatial effect on PD-L1 expression has recently been highlighted in a study on 
lung cancer patients with brain metastasis. Dong and colleagues found a significant difference 
between different cancer sites and concluded that the PD-1/PD-L1 axis is strongly influenced by the 
tumor surrounding microenvironment.30  
There are several limitations to this study. First, it is a single-center, retrospective analysis with only a 
limited number of patients, thus deductions have to be interpreted with caution. We currently 
recruit patients within an international multi-institutional study protocol in order to confirm the 
impact of proposed prognostic markers in CRC PM in a larger cohort. Second, a selection bias cannot 
be excluded. Patients undergoing PM are a highly selected subset of patients, who do not necessarily 
represent all patients with lung metastases. One strength of this study is that IHC analysis were 
performed on full slides, rather than using tissue microarrays (TMA).11, 19 Although TMA facilitate the 
analysis of a large number of samples, tissue analysis is limited to a small cylinders of less than one 
mm in diameter.31 In our study the size of obtained tissue samples was approximately 10-20mm and 
four different random spots were used for analysis. This technique minimized the possibility of bias 
due to tumor heterogeneity. 
In conclusion, this study shows that PD-1 and PD-L1 are uniformingly expressed in tumor cells and 
TILs of resected CRC pulmonary metastases. High expression of PD-1 in TILs reflects an aggressive 
tumor biology with impaired overall survival. Further studies are warranted to confirm these findings 
in a larger study cohort. 
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Figure Legends 
 
Figure 1 shows representative slides of PD-1 and PD-L1 expressing tumor-infiltrating lymphocytes. 
Patients were dichotomized into PD1low (0-50% positive cells) PD1high (51-100% positive cells). 
 
Figure 2 depicts the correlation of PD-1 and PD-L1 expression between lung metastases and 
corresponding primary tumors. There was a broad inconsistency within the study population with 
either up- or downregulation of PD-1 and PD-L1 expression in TILs and tumor cells. 
 
Figure 3. Kaplan-Meier plots of PD-1/TILs on patients’ outcome. PD-1 expression on tumor-infiltrating 
lymphocytes did not impact time to recurrence after pulmonary metastasectomy (A), but was 
significantly associated with an impaired overall survival (B). Patients with an upgrading of their PD-
1/TIL status had the worst prognosis (C). 
 
Figure 4.  Kaplan-Meier plots of PD-L1/TILs on patients’ outcome. In contrast to PD-1, PD-L1 was only 
loosely associated with outcome parameters. A non-significant trend towards worse overall survival 
in the group of PD-L1 high-expressing TILs was observed (B). Additionally, upgrading of PD-L1/TIL 
resulted in an impaired prognosis (C). 
 
 
Table 1. Patients’ characteristics 
 
Table 2. Detailed list of PD-1, PD-L1 and PD,L2 expression on tumor cells and tumor-infiltrating 
lymphocytes in pulmonary metastases and corresponding primary tumors. 
 
Table 3. Association of PD-1 and PD-L1 expression with clinicopathological characteristics 
 
Table 4. Univariate outcome analysis of recurrence-free survival and overall survival after pulmonary 
metastasectomy 
 
Suppl. Table 1. Changes in PD-1 and PD-L1 expression between metastasis and corresponding 
primary   
Table 1 - Patients' characteristics
Total study cohort
(n=53)
n %
Median age at surgery (range) 64 (33-79)
Median follow-up after metastasectomy in months (range) 35 (4-137)
Sex 
    Male 30 56.6
    Female 23 43.4
Localization of primary tumor 
    Colon 30 56.6
    Rectum 23 43.4
T stage
    -1 1 2.0
    -2 6 12.0
    -3 36 72.0
    -4 7 14.0
    unknown 3 -
N stage
    -0 21 42.0
    -1 14 28.0
    -2 15 30.0
    unknown 3 -
UICC stage of primary tumor 
    I 4 8.0
    II 13 26.0
    III 24 48.0
    IV 9 18.0
    unknown 3 -
Previous liver metastasis 
    Yes 16 30.2
    No 37 69.8
Lung metastasis free survival
    <36 months 32 60.4
    36-60 months 8 15.1
    60 months 9 17.0
No. of pulmonary metastases 
    singular 40 75.5
    multiple 13 24.5
Chemotherapy before metastasectomy 
    Yes 42 79.2
    No 11 20.8
Chemotherapy after metastasectomy 
    Yes 40 75.5
    No 13 24.5
Suppl. Table 1 - Changes in PD-1 and PD-L1 expression between metastasis and corresp    
n % n %
downgrading 6 22.2 11 37.9
same grade 7 25.9 12 41.4
upgrading 14 51.9 6 20.7
TILs Tumor cells
PD-1
             onding primary  
n % n %
7 26.9 6 21.4
15 57.7 11 39.3
4 15.4 11 39.3
TILs Tumor cells
PD-L1
Table 2 - PD1, PD-L1 and PD-L2 Expression
n % n % n % n %
PD-1
    negative 5 9.6 5 9.6 4 13.3 2 6.7
    1-25% 15 28.8 5 9.6 17 56.7 4 13.3
    16-50% 16 30.8 7 13.5 4 13.3 5 16.7
    51-75% 13 25 9 17.3 5 16.7 8 26.7
    76-100% 3 5.8 26 50.0 0 0.0 11 36.7
PD-L1
    negative 10 19.6 15 29.4 5 16.7 13 43.3
    1-25% 33 64.7 27 52.9 19 63.3 15 50.0
    16-50% 8 15.7 5 9.8 6 20.0 1 3.3
    51-75% 0 0.0 4 7.8 0 0.0 1 3.3
    76-100% 0 0.0 0 0.0 0 0.0 0 0.0
PD-L2
    negative 52 100.0 49 94.2 30 100.0 25 83.3
    1-25% 0 0.0 3 5.8 0 0.0 2 6.7
    16-50% 0 0.0 0 0.0 0 0.0 3 10.0
    51-75% 0 0.0 0 0.0 0 0.0 0 0.0
    76-100% 0 0.0 0 0.0 0 0.0 0 0.0
n %
CD3
    scattered (+) 6 14.3
    intermediate (2+) 14 33.3
    dense infiltrate (3+) 16 38.3
    very dense infiltrate (4+) 6 14.3
CD8
    none (-) 2 4.7
    sparse (+) 21 48.8
    intermediate (2+) 11 25.6
    high (3+) 9 20.9
CD45RO
    none (-) 4 9.5
    sparse (+) 13 31
    intermediate (2+) 23 54.8
    high (3+) 2 4.8
Metastasis Primary tumor
TILs Tumor cellsTILs Tumor cells
Table 3 - Association of PD-1 and PD-L1 expression with clinicopathological characteristics 
low high p low high p negative positive p negative positive p
Age at surgery 
    <64 19 7 10 16 3 23 6 20
    ≥64 17 9 7 19 7 18 9 16
Sex
    Male 18 11 8 21 4 24 7 21
    Female 18 5 9 14 6 17 8 15
Localization of primary tumor
    Colon 20 10 9 21 2 28 6 24
    Rectum 16 6 8 14 8 13 9 12
UICC stage of primary tumor
    I 2 1 1 2 1 1 1 1
    II 9 4 4 9 2 11 3 10
    III 18 6 9 15 5 19 7 17
    IV 4 5 2 7 2 7 3 6
    unknown (n=3)
Previous liver metastasis
    No 25 11 10 26 6 29 10 25
    Yes 11 5 7 9 4 12 5 11
Lung metastasis free survival
    <36 months 22 9 10 21 6 25 10 21
    36-60 months 6 2 3 5 2 6 3 5
    60 months 6 3 2 7 1 7 1 7
No. of pulmonary metastases
    singular 27 12 12 27 6 32 9 29
    multiple 9 4 5 8 4 9 6 7
Lymphatic vessel invasion
    No 25 7 12 20 6 25 8 23
    Yes 11 9 5 15 4 16 7 13
Chemotherapy before metastasectomy 
    No 6 4 3 7 1 9 2 8
    Yes 30 12 14 28 9 32 13 28
Chemotherapy after metastasectomy 
    No 7 5 4 8 2 10 3 9
    Yes 29 11 13 27 8 31 12 27
0.482 0.840 0.393 0.466
0.351 0.957 0.769 0.701
1.000 0.609 0.240 0.125
0.079 0.350 0.955 0.482
0.960 0.257 0.512 0.846
0.931 0.778 0.816 0.482
0.640 0.629 0.005 0.078
0.422 0.868 0.735 0.866
0.209 0.378 0.291 0.446
Tumor-infiltrating lymphocytes
0.548 0.375
Tumor-infiltrating lymphocytesTumor cells
PD-1 PD-L1
Tumor cells
0.139 0.311
Table 4 - Univariate outcome analysis of recurrence-free survival and overall survival after pulmonary metastasectomy
mean survival (months) p-value mean survival (months) p-value
Sex Male 17 (9-25) 67 (49-84)
Female 31 (17-33) 66 (44-87)
Age (years) < 64 yrs 22 (13-32) 51 (39-62)
≥ 64 yrs 26 (15-38) 69 (49-89)
Location Colon 19 (13-25) 68 (48-88)
Rectum 28 (16-40) 53 (41-65)
UICC stage I + II 23 (12-35) 43 (32-55)
III + IV 26 (17-36) 87 (66-107)
Chemotherapy before metastasectomy Yes 24 (16-33 70 (53-87)
No 26 (10-41) 45 (30-59)
Chemotherapy after metastasectomy Yes 22 (15-29) 59 (46-71)
No 29 (10-48) 97 (70-125)
Previous liver metastasis Yes 14 (7-21) 49 (34-63)
No 30 (20-40) 70 (52-88)
Lung metastasis free survival <36 23 (15-31) 69 (50-89)
>=36 22 (12-32) 55 (41-69)
Number of metastasis singular 20 (14-25) 72 (54-89)
multiple 33 (14-53) 56 (28-84)
PD1 - Tumor infiltrating lymphocytes low 24 (16-33) 78 (60-96)
high 24 (12-35) 35 (25-44)
PD1 - Tumor cells low 28 (14-41) 83 (57-109)
high 21 (15-28) 59 (45-74)
PD-L1 - Tumor infiltrating lymphocytes negative 15 (6-23) 38 (29-46)
positive 26 (17-35) 73 (55-90)
PD-L1 - Tumor cells negative 16 (10-23) 74 (51-98)
positive 26 (17-35) 71 (52-89)
0.952
0.448
Recurrence-free survival Overall survival
0.766
Univariate analysis (log-rank)
0.081
0.857
0.796
0.721
Univariate analysis (log-rank)
0.931
0.551
0.011
0.269
0.447
0.683
0.589
0.055
0.685
0.714
0.743
0.061
0.538
0.425
0.307
0.628
0.918
0.310
0.538
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